首页 Illumina(usILMN)-基本信息

Illumina(usILMN)-基本信息

日报更新时间:04-17 11:30

周报更新时间:04-11 03:39

行情信息

今开价:401.89

最高价:402.39

成交量:1176777.0

昨收价:401.96

最低价:390.52

最新价:399.0

行情图标
概要信息

英文名称:Illumina


行业:医疗


简介:Illumina, Inc.是一家生命科学用具以及用于分析基因变异和基因功能的整合系统的一流开发商、制造商和销售商


电话:1-858-2024500


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

Illumina公司的测序合成技术提供研究人员与各种应用程式和序列哺乳动物基因组的能力。Illumina公司也提供了一系列的脱氧核糖核酸的阵列和RNA分析应用,包括单核苷酸多态性基因分型,拷贝数目变异分析,基因表现分析,与甲基化分析,以及允许单个阵列上已知的基因标记的检测。此外,Illumina公司还提供各种文库制备和测序工具包以简化工作流程加快分析。还有基因组测序,基因分型和无侵入产前检测服务。Illumina发展基因变异和作用的大规模分析工具,提供用于改进药物和疗法、特殊诊断和治疗,以及治疗疾病的信息,是遗传变异和生物学功能分析领域的优秀的产品、技术和服务供应商。通过帮助客户加快实现生物信息的采集、分析和应用,来改善人类健康。Illumina公司提供服务给基因组研究中心,学术机构,政府实验室和医院,以及医药,生物技术,农业基因组合,商业分子诊断实验室和消费者基因公司。Illumina公司销售和直接分销售其产品给在北美,欧洲,拉美和亚太地区的客户,同时也通过生命科学的分销商。Illumina(ILMN)历史百科: 1998年4月1日,Illumina公司由David Walt博士(Tufts University,BeadArray技术投资者)、Larry Bock(CW Group)、John Stuelpnagel、D.V.M.、Anthony Czarnik博士及Mark Chee博士创立; 2000年7月1日,Illumina股票IPO; 2001年,推出快速基因分型服务——并在2001年5月与葛兰素史克(GlaxoSmithKline)签订第一个服务合同; 2002年,Illumina推出BeadLab 系统,国际HapMap计划第1阶段中超过60%的数据都是利用该平台和GoldenGate检测产生的; 2003年9月1日,推出基因表达阵列(基因表达谱分析); 2004年,Illumina推出BeadStation系统——一个台式解决方案,能运行DNA和RNA分析应用; 2004年1月1日,推出DASL Assay检测——一种强大的新方法,能让部分降解RNA样品(如福尔马林固定、石蜡包埋的样品)生成基因表达谱; 2005年2月1日,Illumina收购CyVera——VeraCode技术(一种互补性的低-多重技术,适用于靶点验证和分子检测开发)的开发商; 2005年2月5日,推出全基因组基因表达阵列; 2005年年中,Illumina推出Infinium全基因组基因分型——一款革命性的基因分型检测,能提供智能的SNP选择和基因组的无限调用; 2005年9月1日,推出全基因组表达阵列; 2006年1月1日,推出Infinium HumanHap300 芯片; 2006年3月1日,Illumina扩展了标准的GoldenGate基因分型板,推出三种新板,分别用于MHC区域、癌症和样品质量评估; 2006年3月1日,Illumina推出Infinium HumanHap550 芯片; 2006年6月1日,推出Infinium HumanHap550+ 和 iSelect 产品; 2006年6月1日,Illumina推出Infinium HumanHap650Y 芯片; 2006年8月1日,推出合格服务供应商活动; 2006年9月21日,推出大鼠全基因组基因表达阵列; 2006年11月1日,Illumina宣布以6亿美元收购基因测序公司Solexa,从而进军基因测序市场,Solexa的基因测试技术较竞争对手快百倍,且价格低廉; 2007年1月10日,推出Infinium Human1M and Human450S 芯片和高通量DNA甲基化癌症模板(GoldenGate Methylation Cancer Panel); 2007年3月12日,Illumina推出Infinium HumanCNV370-Duo 芯片(与deCODE genetics合作开发); 2007年3月21日,推出BeadXpress系统; 2007年4月16日,Illumina推出自定义DNA甲基化; 2007年5月1日,推出IlluminaConnect(一个生物信息学软件合作计划,为加速数据整合和分析而建立); 2007年6月11日,提供行业内第一个数据库控制——iControlDB; 2007年7月24日,推出新的数字基因表达(DGE)应用; 2007年8月2日,Illumina推出Infinium HumanHap550-Duo 芯片 2007年9月6日,推出Infinium HumanLinkage-12芯片; 2007年10月22,推出使用BeadArray技术的MicroRNA 测试(目前唯一一个仅以市场上其他方法一半的价格实现快速可重复的miRNA表达谱分析的工具,每个样品的价格为95美元); 2007年10月25日,推出Infinium DNA 甲基化芯片; 2008年1月4日,Illumina宣布公司重组,以便进一步利用测序和基因分型业务的协同优势; 2008年1月7日,推出高密度产品线——Infinium HD Human1M-Duo(两个样品/芯片)和Human610-Quad(四个样品/芯片); 2008年1月15日,发行Infinium BovineSNP50 芯片——能检测任何牛品种的基因变异; 2008年2月6日,Illumina测出第一个非洲人基因组的序列; 2013年,收购了无创产前诊断公司Verinata Health; 2014年1月,Illumina发布了新款高端基因测序仪,可以准确测出全基因组序列,而成本还不到1000美元; 2014年2月,MIT发布的“2014年度全球创新企业50强”,Illumina高居生物科技公司榜首; 2016年1月26日,Illumina宣布,公司已经收购了澳洲的HLA分型解决方案供应商Conexio Genomics,交易的具体条款没有披露。早在2015年3月,llumina首次与Conexio合作提供TruSight HLA解决方案。此次收购将使Illumina开发NGS-based移植手术诊断化验产品技术。此次对Conexio的收购或将加强Illumina开发基于下一代测序技术的移植手术诊断化验的能力。Conexio产品和人员的加入将巩固其HLA能力,并证明Illumina对HLA(人类白细胞抗原)和移植科学领域的持续承诺,Conexio的 NGS开发项目将并入Illumina的现有业务单元。

交易日期 交易人 职位 类型 交易份额 价格
2019-07-31 Dadswell (Charles E) General Counsel Sell 124 300.00
2019-07-31 deSouza (Francis A) Chief Executive Officer Sell 100 303.47
2019-07-31 deSouza (Francis A) Chief Executive Officer Sell 700 302.69
2019-07-31 deSouza (Francis A) Chief Executive Officer Sell 400 299.23
2019-07-31 deSouza (Francis A) Chief Executive Officer Sell 700 301.76
2019-07-31 deSouza (Francis A) Chief Executive Officer Sell 1100 300.55
2019-07-28 Ronaghi (Mostafa) Chief Technology Officer Sell 191 304.41
2019-07-23 Flatley (Jay T) Director Sell 3300 304.00
2019-07-14 Ronaghi (Mostafa) Chief Technology Officer Sell 5716 301.93
2019-07-14 Ronaghi (Mostafa) Chief Technology Officer Sell 2717 301.16
2019-07-14 Ronaghi (Mostafa) Chief Technology Officer Buy 10000 69.34
2019-07-14 Ronaghi (Mostafa) Chief Technology Officer Sell 500 305.40
2019-07-14 Ronaghi (Mostafa) Chief Technology Officer Sell 300 304.14
2019-07-14 Ronaghi (Mostafa) Chief Technology Officer Sell 767 302.95
2019-07-09 Flatley (Jay T) Director Sell 3300 376.50
2019-07-04 deSouza (Francis A) Chief Executive Officer Sell 336 378.23
2019-06-30 deSouza (Francis A) Chief Executive Officer Sell 607 370.34
2019-06-30 deSouza (Francis A) Chief Executive Officer Sell 544 368.27
2019-06-30 deSouza (Francis A) Chief Executive Officer Sell 1849 369.67
2019-06-30 Dadswell (Charles E) General Counsel Sell 124 371.29
2019-06-25 Flatley (Jay T) Director Sell 3300 358.15
2019-06-16 Ronaghi (Mostafa) Chief Technology Officer Sell 2964 350.62
2019-06-16 Ronaghi (Mostafa) Chief Technology Officer Sell 1000 349.26
2019-06-16 Ronaghi (Mostafa) Chief Technology Officer Sell 1281 351.30
2019-06-16 Ronaghi (Mostafa) Chief Technology Officer Sell 299 352.39

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Northern Trust Investments N A 1660761 1.13% 14669 0.89% 2019-03-31
BlackRock Fund Advisors 4961770 3.38% -129069 -2.54% 2019-07-31
Jennison Associates LLC 5679678 3.86% 200114 3.65% 2019-03-31
Capital Research Global Investors 5995837 4.08% -87454 -1.44% 2019-03-31
State Street Corporation 6164846 4.19% 369479 6.38% 2019-03-31
Capital Research and Management Company 8283756 5.64% -2456890 -22.87% 2019-07-31
Vanguard Group Inc 11494167 7.82% -5894 -0.05% 2019-03-31
BlackRock Inc 10778604 7.33% -722452 -6.28% 2019-03-31
Baillie Gifford & Co Limited. 15975291 10.87% -102991 -0.64% 2019-03-31
Vanguard 4714738 3.21% -142709 -2.94% 2019-07-31
Vanguard Investments Australia Ltd 4113599 2.80% 21829 0.53% 2019-07-31
Edgewood Management LLC 4110928 2.80% 18744 0.46% 2019-03-31
TIAA-CREF Investment Management LLC 1732216 1.18% 318944 22.57% 2019-03-31
Harbor Capital Advisors Inc 1917871 1.30% 147060 8.30% 2019-07-31
Geode Capital Management, LLC 1934381 1.32% -1774311 -47.84% 2019-03-31
State Street Global Advisors 2450260 1.67% -1534 -0.06% 2019-07-31
Morgan Stanley Investment Management, Inc. 2696903 1.83% 158648 6.25% 2019-03-31
Morgan Stanley - Brokerage Accounts 3107623 2.11% -8745 -0.28% 2019-03-31
Sands Capital Management, LLC 3717886 2.53% -98627 -2.58% 2019-03-31
Capital Research & Mgmt Co - Division 3 3970368 2.70% -585 -0.01% 2019-03-31
Northern Trust Corp 1660761 1.13% 14669 0.89% 2019-03-31
Amvescap Plc. 2700332 1.84% 225205 9.10% 2018-12-31
BlackRock Japan Co Ltd 2163142 1.47% 1936 0.09% 2019-05-31
BlackRock Asset Management Canada Ltd 4597226 3.13% 5711 0.12% 2019-05-31
JPMorgan Chase & Co 1954329 1.33% 282245 16.88% 2018-09-30
Bank of New York Mellon Corp 1713373 1.17% -26386 -1.52% 2018-12-31
Ameriprise Financial Inc 1955096 1.33% -189359 -8.83% 2018-09-30
BlackRock Institutional Trust Company NA 3602179 2.45% -361904 -9.13% 2018-06-30
Winslow Capital Management, LLC 1813718 1.23% 875331 93.28% 2018-06-30
Capital World Investors 2384800 1.62% -635200 -21.03% 2018-06-30
T. Rowe Price Associates, Inc. 1836652 1.25% -291608 -13.70% 2018-06-30
Columbia Mgmt Investment Advisers, LLC 1766455 1.20% -252682 -12.51% 2018-06-30
Growth Fund of America Inc 8051971 5.52% -232486 -2.81% 2017-12-29
State Street Corp 5429848 3.69% -122814 -2.21% 2018-06-30
State Street Global Advisors (Aus) Ltd 1692944 1.15% 40179 2.43% 2018-09-12
Morgan Stanley Investment Management Inc 3058811 2.08% -25257 -0.82% 2018-06-30
Columbia Mangmt Investment Advisers, LLC 1766455 1.20% -252682 -12.51% 2018-06-30
Invesco PowerShares Capital Mgmt LLC 1579571 1.07% 333457 26.76% 2018-06-30
Wellington Management Company LLP 1308600 0.89% -97630 -6.94% 2018-06-30
Franklin Advisers Inc 1370569 0.93% -98387 -6.70% 2018-06-30
PRIMECAP Management Company 1873520 1.28% -13840 -0.73% 2018-03-31
J.P. Morgan Investment Management Inc 1458107 0.99% -171458 -10.52% 2018-03-31
BlackRock Advisors LLC 1088313 0.74% -418602 -27.78% 2016-09-30
BlackRock Inc. 8097401 3.00% 1503201522 0.10% 1999-11-30
Viking Global Investors LP 8189589 3.00% 1520315302 0.10% 1999-11-30
Baillie Gifford&Co. 13363317 3.00% 2147483647 0.10% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Health Care Select Sector SPDR 745869 0.51% 5880 0.79% 2019-07-31
Harbor Capital Appreciation Fund 1917871 1.30% 147060 8.30% 2019-06-30
Edgewood Growth Fund 2045747 1.39% 21257 1.05% 2019-04-30
Scottish Mortgage Inv Tr 2571056 1.75% 666 0.03% 2019-05-31
American Funds AMCAP Fund 2663757 1.81% -231500 -8.00% 2019-06-30
Vanguard International Growth Fund 2734956 1.86% -- -- 2019-03-31
Vanguard 500 Index Fund 2892820 1.97% 29123 1.02% 2019-06-30
American Funds Growth Fund of Amer 3672209 2.50% -1399027 -27.59% 2019-06-30
Vanguard Total Stock Market Index Fund 4054277 2.76% 21675 0.54% 2019-06-30
SPDR 1631928 1.11% -4488 -0.27% 2019-07-31
iShares Nasdaq Biotechnology ETF 1388502 0.94% 14450 1.05% 2019-07-30
Vanguard Institutional Index Fund 1372593 0.93% -10463 -0.76% 2019-06-30
Baillie Gifford L/T Glb Gr Invmt Fd 904645 0.62% -- -- 2019-05-31
JPMorgan Large Cap Growth Fund 912175 0.62% -- -- 2019-06-30
CREF Growth Account 1008661 0.69% 1237 0.12% 2019-06-30
Vanguard Growth Index Fund 1050417 0.71% 34766 3.42% 2019-06-30
Morgan Stanley Inst Growth Port 1075878 0.73% 49146 4.79% 2019-03-31
iShares Core S&P 500 ETF 1081831 0.74% -534 -0.05% 2019-07-30
Fidelity 1190388 0.81% 17561 1.50% 2019-06-30
Invesco QQQ Trust 1320275 0.90% 1162 0.09% 2019-07-31
American Funds Invmt Co of Amer 1000000 0.68% -- -- 2019-03-31
iShares MSCI World ETF 1081571 0.74% 968 0.09% 2019-05-30
iShares Core MSCI AllCntry Wld exCan ETF 1081571 0.74% 968 0.09% 2019-05-30
iShares Core MSCI Kokusai ETF 1081571 0.74% 968 0.09% 2019-05-30
iShares Core S&P US Total Market ETF 1081571 0.74% 968 0.09% 2019-05-30
iShares Core S&P 500 ETF (CAD-Hedged) 1081571 0.74% 968 0.09% 2019-05-30
iShares S&P 500 ETF 1081571 0.74% 968 0.09% 2019-05-30
VA CollegeAmerica The Gr Fd of Amer 4992713 3.40% -2189728 -30.49% 2018-12-31
VA CollegeAmerica AMCAP Fd 2895257 1.97% -40000 -1.36% 2018-12-31
VA CollegeAmerica The Inv Co of Amer 1000000 0.68% -100000 -9.09% 2018-12-31
Vanguard Morgan 824539 0.56% 446880 118.33% 2018-12-31
OH Putnam Fidelity Spartan 500 Index 1101258 0.75% 31864 2.98% 2019-01-31
Vanguard Health Care Fund 787788 0.54% -426700 -35.13% 2018-09-30
Edgewood L Select US Select Growth 732464 0.50% -49602 -6.34% 2018-10-31
Harbor Capital Appreciation Instl 1459805 0.99% -24120 -1.63% 2018-06-30
MainStay Large Cap Growth A 576400 0.39% -3900 -0.67% 2018-07-31
Vanguard Total Stock Mkt Idx 3694666 2.51% 14890 0.40% 2018-07-31
Vanguard 500 Index Inv 2662237 1.81% 3776 0.14% 2018-07-31
VA CollegeAmerica Amcap 529F 3012257 2.05% 616302 25.72% 2018-06-30
Edgewood Growth Instl 2411763 1.64% -94949 -3.79% 2018-07-31
Vanguard International Growth Inv 2734956 1.86% -- -- 2018-06-30
iShares Nasdaq Biotechnology 1631228 1.09% -3105 -0.19% 2018-09-12
Vanguard Institutional Index I 1422565 0.97% 1964 0.14% 2018-07-31
PowerShares QQQ ETF 1204395 0.82% -4650 -0.38% 2018-09-13
VA CollegeAmerica Invmt Co of Amer 529E 1425000 0.97% 61785 4.53% 2018-06-30
Vanguard Health Care Inv 1214488 0.83% -143400 -10.56% 2018-06-30
Vanguard Growth Index Inv 1035620 0.70% -2685 -0.26% 2018-07-31
Fidelity Spartan 979196 0.67% 11550 1.19% 2018-07-31
Morgan Stanley Inst Growth I 1026732 0.70% -- -- 2018-06-30
CREF Growth R1 709336 0.48% -54448 -7.13% 2018-07-31
CREF Stock R1 588245 0.40% -26388 -4.29% 2018-07-31
VA CollegeAmerica Grth Fund of Amer 529F 8191941 5.57% 7498 0.09% 2018-06-30
Franklin Growth Fund A 525000 0.36% -- -- 2018-07-31
Vanguard Capital Opportunity Inv 1037400 0.71% -5000 -0.48% 2018-03-31
American Funds NVIT Growth II 775000 0.53% -- -- 2018-03-31
American Funds NVIT Growth-Income II 867550 0.59% -22750 -2.56% 2017-12-31
T. Rowe Price Mid-Cap Growth 750000 0.51% -50000 -6.25% 2017-12-31
T. Rowe Price Growth Stock 1191620 0.81% 37752 3.27% 2016-09-30
VA CollegeAmerica Cap World G/I 529E 918382 0.63% -- -- 2016-12-31
Columbia Select Large Cap Growth Z 870922 0.59% -58622 -6.31% 2016-12-31
Columbia Select Large Cap Growth Fund 1495252 1.00% 178580 13.60% 2015-09-30
Vanguard Extended Market Index Fund 1485013 1.00% 16415 1.10% 2015-10-31
Artisan Mid Cap Fund 1450311 1.00% -182125 -11.20% 2015-09-30
SPDR® S&P 500 ETF 1412230 1.20% 8528 0.60% 2015-11-27
VA CollegeAmerica AMCAP 1268510 0.90% 236000 22.90% 2015-09-30
Vanguard Capital Opportunity Fund 1220100 0.80% -- -- 2015-09-30
PowerShares QQQ 1160653 1.00% -- -- 2015-11-29
Morgan Stanley Inst Mid Cap Growth Port 1135019 0.80% -398486 -26.00% 2015-09-30
VA CollegeAmerica Growth Fund of America 6022501 4.20% 850000 16.40% 2015-09-30

Arthur Blaine Bowman Arthur Blaine Bowman is Chairman at ProteinSimple, Inc. He is also on the board of Illumina, Inc. and IO Informatics, Inc. In his past career he was Management Consultant at McKinsey & Co., Inc., Director at Dionex Corp. and Product Engineer-Semiconductor Products Division at Motorola, Inc. Mr. Bowman received an undergraduate degree from Brigham Young University and an MBA from Stanford University.
Robert P. Ragusa Presently, Robert P. Ragusa holds the position of Senior Vice President-Global Quality & Operations at Illumina, Inc. He is also on the board of Twist Bioscience Corp. In his past career he occupied the position of Executive VP-Engineering & Global Operations at Accuray, Inc., Senior Vice President-Global Operations at Applied Biosystems, Inc. and Vice President for Applera Corp. Robert P. Ragusa received a graduate degree from Carnegie Mellon University and an undergraduate degree and an MBA from the University of Connecticut.
Robert S. Epstein Robert S. Epstein is on the board of Illumina, Inc. and 4 other companies. In the past Dr. Epstein was President of Medco Research Institute LLC, President of Health Outcomes Research Europe SL, Chief Research & Development Officer at Medco Health Solutions, Inc. and President at International Society for Pharmacoeconomics & Outcomes Rsch. He received a doctorate and an undergraduate degree from the University of Michigan and a graduate degree from the University of Maryland.
Caroline D. Dorsa Caroline D. Dorsa is on the board of Biogen, Inc. and 10 other companies. In the past she was Chief Financial Officer & Senior Vice President at Gilead Sciences, Inc., Chief Financial Officer & Executive Vice President at Public Service Enterprise Group, Inc. Chief Financial Officer, Director & Executive VP at PSEG Power LLC, Chief Financial Officer & Executive Vice President for Public Service Electric & Gas Co. Chief Financial Officer of PSEG Energy Holdings LLC and Chief Financial Officer & Executive Vice President for PSEG Services Corp. (which are all subsidiaries of Public Service Enterprise Group, Inc.), SVP-Global Human, Health, Strategy & Integration at Merck & Co., Inc. and Chief Financial Officer & Senior Vice President of Avaya, Inc. She received an undergraduate degree from Colgate University and an MBA from Columbia Business School.
Karen K. McGinnis Ms. Karen K. McGinnis, CPA, is a Chief Accounting Officer & Vice President at Illumina, Inc. She is on the Board of Directors at Alphatec Holdings, Inc. and Alphatec Spine, Inc. Ms. McGinnis was previously employed as a President, Chief Executive Officer & Director by Mad Catz Interactive, Inc., a Chief Accounting Officer, VP & Controller by Cymer, Inc., and a Chief Accounting Officer by Insight Enterprises, Inc. She received her undergraduate degree from the University of Oklahoma.
Ostadan Omead Ostadan Omead is Senior VP-Products, Marketing & Strategic Planning at Illumina, Inc. He previously occupied the position of Vice President-Marketing at Solexa, Inc. Mr. Omead received an undergraduate degree from the University of California, Davis and an MBA from The Wharton School of the University of Pennsylvania.
Karin Eastham Karin Eastham is on the board of Nektar Therapeutics and 4 other companies. In her past career she occupied the position of Vice President-Finance & Administration at Paper Art Co., Inc., CFO, Secretary & Senior Vice President-Finance at Diversa Corp., CFO, Secretary & Senior Vice President-Finance at Cytel Corp., Vice President-Finance at Roche Diagnostics Corp., CFO, Secretary & Senior Vice President-Finance at CombiChem, Inc., Vice President-Finance & Administration at Pritsker Corp, Vice President-Finance for Boehringer Mannheim Diagnostics Corp. and Chief Operating Officer, Trustee & Executive VP at Sanford Burnham Prebys Medical Discovery Institute. She received an MBA and an undergraduate degree from Indiana University.
Philip W. Schiller Philip W. Schiller occupies the position of Senior Vice President-Worldwide Marketing at Apple, Inc. He is also on the board of Illumina, Inc. In the past Mr. Schiller occupied the position of Manager-Information Technology at Nolan, Norton & Co., Director-Product Marketing at FirePower Systems, Inc. and Vice President-Product Marketing at Macromedia, Inc. Mr. Schiller received an undergraduate degree from Boston College.
John Wendell Thompson Dr. John W. Thompson is a Venture Partner at Lightspeed Management Co. LLC, an Independent Director at Illumina, Inc., an Independent Chairman at Microsoft Corp. and a Member at National Infrastructure Advisory Council. He is on the Board of Directors at Rubrik, Inc., Illumina, Inc., Illumio, Inc., JovianDATA, Inc., Liquid Robotics, Inc. and Wetlands America Trust, Inc. Dr. Thompson was previously employed as a Chief Executive Officer & Director by Virtual Instruments Corp., an Independent Director by United Parcel Service, Inc., a Chairman by Symantec Corp., and a General Manager by International Business Machines Corp. He also served on the board at Seagate Technology Plc, Beam Suntory, Inc., Crystal Decisions, Inc., Domo, Inc., NiSource, Inc., Northern Indiana Public Service Co., Seagate Technology LLC and Teach For America, Inc. He received his undergraduate degree from Florida A&M University and a graduate degree from MIT Sloan School of Management.
Jay T. Flatley Jay T. Flatley is a businessperson who founded Bruker AXS, Inc. and Molecular Dynamics, Inc. and who has been at the helm of 5 different companies. He is Chairman for Helix OpCo LLC and Executive Chairman at Illumina, Inc. Jay T. Flatley is also on the board of 7 other companies. In the past Mr. Flatley was Chairman at GRAIL, Inc. (California), VP-Engineering & Strategic Planning at Plexus Computers LLC, Executive Vice President for Manning Technologies, Inc., President, Chief Executive Officer & Director at Molecular Dynamics, Inc., President & Chief Executive Officer at Bruker AXS, Inc. and Executive Vice President-Manning Technologies at Spectra-Physics, Inc. Jay T. Flatley received an undergraduate degree and a graduate degree from Stanford University and an undergraduate degree from Claremont McKenna College.
Gary S. Guthart Currently, Gary S. Guthart occupies the position of President, Chief Executive Officer & Director at Intuitive Surgical, Inc. Dr. Guthart is also on the board of Illumina, Inc. He received an undergraduate degree from the University of California, Berkeley and a graduate degree and a doctorate from California Institute of Technology.
Francis A. deSouza Francis A. deSouza is a businessperson who founded Flash Communications and IMlogic, Inc. and who has been at the head of 5 different companies. Presently, Mr. DeSouza holds the position of President, Chief Executive Officer & Director at Illumina, Inc. and Chief Executive Officer for Verinata Health, Inc. (a subsidiary of Illumina, Inc.). Francis A. deSouza is also on the board of The Walt Disney Co. and Chairman for Medhelp International. In his past career Mr. DeSouza occupied the position of Chief Executive Officer of Flash Communications, President-Enterprise Products & Services at Symantec Corp. and Chief Executive Officer at IMlogic, Inc. (a subsidiary of Symantec Corp.), Manager-Product Unit at Microsoft Corp. and Advisor at Kodiak Venture Partners. He received a graduate degree and an undergraduate degree from Massachusetts Institute of Technology.
Ostadan Omead Ostadan Omead is Senior VP-Products, Marketing & Strategic Planning at Illumina, Inc. He previously occupied the position of Vice President-Marketing at Solexa, Inc. Mr. Omead received an undergraduate degree from the University of California, Davis and an MBA from The Wharton School of the University of Pennsylvania.
Mostafa Ronaghi Founder of 5 different companies, including: Biotage AB, Avantome, Inc. and ParAllele BioScience, Inc. Mostafa Ronaghi is an entrepreneur and presently is Chief Technology Officer & Senior Vice President of Illumina, Inc. He is also on the board of BaseHealth, Inc. and Clear Labs, Inc. He previously occupied the position of Chairman & Chief Scientific Officer at Avantome, Inc. (he founded the company in 2008), Principal Investigator at Stanford University, Director at NextBio Corp. and Director at ParAllele BioScience, Inc. Mostafa Ronaghi received a doctorate from Royal Institute of Technology.
Susan E. Siegel Susan E. Siegel is a businessperson who founded Stanford Health Care and who has been the head of 5 different companies. She is on the board of Illumina, Inc., Align Technology, Inc., The Tech Museum of Innovation and RAND Health and Member-Innovation Council at the University of California, Chief Innovation Officer & CEO-Business Innovations at General Electric Co., Council Member-Biotechnology Research at Center for Strategic & International Studies, Inc., Member-Presidents Council at The National Academies of Science, Member of Women Corporate Directors and Member of YPO Golden West. Susan E. Siegel previously occupied the position of Chairman at On-Q-ity, Inc., President for Hoefer Pharmacia Biotech, Inc., General Partner at MDV Management Co. LLC, Principal at Bio-Rad Laboratories, Inc., Partner at MDV Management Co. LLC, Chairman for Crescendo Bioscience, Inc., President & Director at Affymetrix, Inc., Principal at Amersham Biosciences Corp., Principal at E.I. du Pont de Nemours & Co. and Member of The J. David Gladstone Institutes. She received an undergraduate degree from the University of Puerto Rico and a graduate degree from Boston University School of Medicine.
Frances Hamilton Arnold Founder of Gevo, Inc. and Provivi, Inc., Frances Hamilton Arnold is on the board of Illumina, Inc., Provivi, Inc. and Donna & Benjamin M Rosen Bioengineering Center and Member of American Academy of Arts & Sciences, Member of National Academy of Engineering, Member of Institute of Medicine, Member of The National Academies of Science, Member of National Academy of Medicine of United States and Professor at California Institute of Technology. In her past career she occupied the position of Director at Gevo, Inc. Dr. Arnold received an undergraduate degree from Princeton University and a doctorate from the University of California, Berkeley.
Charles E. Dadswell Currently, Charles E. Dadswell occupies the position of Secretary, Senior Vice President & General Counsel at Illumina, Inc. He previously occupied the position of General Counsel at BioDelivery Sciences International, Inc., Vice President-US Intellectual Property at GlaxoSmithKline, Inc., Principal at Glaxo Wellcome, Inc. and Vice President & General Counsel for bioMerieux, Inc. He received an undergraduate degree from Ferris State University (Michigan), a graduate degree from The Thomas M. Cooley Law School and a graduate degree from George Washington University Law School.
Rebecca Chambers Rebecca Chambers holds the position of Treasury at Illumina, Inc. In the past Ms. Chambers held the position of Director-Investor Relations for Myriad Genetics, Inc. and Senior Manager-Investor Relations at Life Technologies Corp.
Aimee Hoyt Currently, Aimee Hoyt is Senior Vice President-Human Resources of Rackspace Hosting, Inc. and Chief People Officer & Senior Vice President at Illumina, Inc. She previously held the position of Vice President-Human Resources at HP, Inc., Director-Human Resources at Cisco Systems, Inc. and Vice President-Human Resources at International Game Technology. She received a graduate degree from Rochester Institute of Technology.
Marc A. Stapley Marc A. Stapley is on the board of Glaukos Corp. and Helix and Member of Institute of Chartered Accountants in England & Wales and EVP-Strategy & Corporate Development at Illumina, Inc. In his past career he held the position of Senior Vice President-Finance for Pfizer Inc., Finance Director & Controller at Cadence Design Systems, Inc., Chief Financial Officer of Alcatel-Lucent USA, Inc. and Auditor for Coopers & Lybrand LLP. Marc A. Stapley received an undergraduate degree from The University of Reading.
Robert S. Epstein Robert S. Epstein is on the board of Illumina, Inc. and 4 other companies. In the past Dr. Epstein was President of Medco Research Institute LLC, President of Health Outcomes Research Europe SL, Chief Research & Development Officer at Medco Health Solutions, Inc. and President at International Society for Pharmacoeconomics & Outcomes Rsch. He received a doctorate and an undergraduate degree from the University of Michigan and a graduate degree from the University of Maryland.
Phillip G. Febbo Currently, Phillip G. Febbo is Chief Medical Officer of Illumina, Inc. Dr. Febbo is also Member of American Society for Clinical Investigation. He previously occupied the position of Chief Medical Officer for Genomic Health, Inc., Professor at The University of California, San Francisco and Associate Professor at Duke University. Phillip G. Febbo received an undergraduate degree from Dartmouth College and a doctorate from The University of California, San Francisco.
Garret Hampton Garret Hampton is Executive Vice President-Clinical Genomics at Illumina, Inc. In his past career he was Senior Director-Oncology Biomarker Development at Genentech, Inc. Dr. Hampton received an undergraduate degree and a graduate degree from Trinity College Dublin and a doctorate from University College London.
Robert P. Ragusa Presently, Robert P. Ragusa holds the position of Senior Vice President-Global Quality & Operations at Illumina, Inc. He is also on the board of Twist Bioscience Corp. In his past career he occupied the position of Executive VP-Engineering & Global Operations at Accuray, Inc., Senior Vice President-Global Operations at Applied Biosystems, Inc. and Vice President for Applera Corp. Robert P. Ragusa received a graduate degree from Carnegie Mellon University and an undergraduate degree and an MBA from the University of Connecticut.
Paula Lynn Dowdy Paula Lynn Dowdy is on the board of AVEVA Group Plc, BlueGnome Ltd. and Illumina Cambridge Ltd. and Senior Vice President at Illumina, Inc. In her past career Ms. Dowdy was Senior VP-Cloud, Software & Managed Services at Cisco, Inc. Ms. Dowdy received an MBA from Pepperdine University School of Law and an undergraduate degree from the University of California.
Sam A. Samad Mr. Sam A. Samad is an Independent Director at IDEXX Laboratories, Inc. and a Chief Financial Officer & Senior Vice President at Illumina, Inc. He is on the Board of Directors at IDEXX Laboratories, Inc. Mr. Samad was previously employed as a Treasurer & Senior Vice President by Cardinal Health, Inc. He received his undergraduate degree from American University of Beirut and an MBA from McMaster University.
Mark David Van Oene Mark David Van Oene is on the board of BlueGnome Ltd. and Illumina Cambridge Ltd. and Chief Commercial Officer & Senior Vice President at Illumina, Inc. In the past he held the position of Director-Genotyping Services at Ellipsis Biotherapeutics Corp. He received an undergraduate degree from the University of Western Ontario.
Jacquie Ross Jacquie Ross is Vice President-Investor Relations of Illumina, Inc.
Susan E. Siegel Susan E. Siegel is a businessperson who founded Stanford Health Care and who has been the head of 5 different companies. She is on the board of Illumina, Inc., Align Technology, Inc., The Tech Museum of Innovation and RAND Health and Member-Innovation Council at the University of California, Chief Innovation Officer & CEO-Business Innovations at General Electric Co., Council Member-Biotechnology Research at Center for Strategic & International Studies, Inc., Member-Presidents Council at The National Academies of Science, Member of Women Corporate Directors and Member of YPO Golden West. Susan E. Siegel previously occupied the position of Chairman at On-Q-ity, Inc., President for Hoefer Pharmacia Biotech, Inc., General Partner at MDV Management Co. LLC, Principal at Bio-Rad Laboratories, Inc., Partner at MDV Management Co. LLC, Chairman for Crescendo Bioscience, Inc., President & Director at Affymetrix, Inc., Principal at Amersham Biosciences Corp., Principal at E.I. du Pont de Nemours & Co. and Member of The J. David Gladstone Institutes. She received an undergraduate degree from the University of Puerto Rico and a graduate degree from Boston University School of Medicine.

量化对比

全部评论 20

  • Illumina(ILMN.O)涨超10%,公司此前预计2021财年营收将同比增长25%至28%。

  • 【道指开盘跌0.2%,标普500跌0.2%,纳指跌0.2%】唯品会跌1.8%,VIACOMCBS跌1.1%,Farfetch跌1.6%,瑞信据悉在大宗交易中出售上述股票。 Illumina涨11.0%,预计2021财年营收将同比增长25%至28%。

  • 富国银行(WFC.N):将Illumina(ILMN.O)目标价从300美元上调至330美元。

  • Illumina(ILMN.O)盘前涨超10%,预计2021财年营收将同比增长25%至28%。

  • 加通贝祥:将Illumina目标价从410美元上调至445美元。

  • 加通贝祥:将Illumina目标价从410美元上调至445美元。

  • Illumina(ILMN)短线跳水30美元,日内整体上转跌,跌幅扩大至5%,刷新日低至374.50美元。美国联邦贸易委员会起诉Illumina竞购贝佐斯持股的Gril,宣称该交易将破坏创新。

  • 穆迪:予Illumina拟发行票据BAA3评级。

  • 【Piper Sandler:上调Illumina目标价】Piper Sandler分析师Steven Mah将Illumina(ILMN.O)目标价从415美元上调至510美元,重申跑赢大市评级,原因是该公司Q4业绩“强劲”。同时,分析师“受到反弹力度的鼓舞”,提高了Q1指引,他认为2021年的数据有上升空间。

  • Piper Sandler:将Illumina(ILMN.O)目标价从415美元升至510美元。

  • 花旗:将Illumina(ILMN.O)目标价从355美元升至460美元。

  • 美国宏桥信托投资集团:将Illumina(ILMN.O)目标价从410美元升至570美元。

  • 投行Stifel:将Illumina目标价从293美元上调至445美元。

  • 投行Stifel:将Illumina目标价从293美元上调至445美元。

  • 加通贝祥:将Illumina(ILMN.O)目标价从350美元升至410美元。

  • 摩根大通:将Illumina(ILMN.O)目标价从280美元升至350美元。

  • 【华大智造关于美国法院初步判决结果的声明】华大智造尊重美国法院针对Illumina 公司提出临时禁令的初步判决结果,但我们不同意这一裁决,并考虑进行上诉以维护自身权益。同时,此次判决结果将不影响华大智造驰援疫情(自动化提取设备及试剂)的在美业务,更不影响华大智造在美国以外地区的业务开展。

  • 【新开源:冠状病毒试剂盒项目有望三周左右提供报批资料】新开源董事长王坚强今日表示,公司同时开展利用Illumina高通量测序平台的“呼吸道冠状病毒试剂盒”及利用荧光定量PCR平台的新型冠状病毒核酸检测试剂盒项目。目前,呼吸道冠状病毒试剂盒项目正加速研发,有望在三周左右提供报批资料,该产品可在较短周期内一次性检测出上千种高致病性病毒基因。此外,荧光定量PCR平台的新型冠状病毒核酸检测试剂盒立项已完成。

  • 【新开源:已立项“呼吸道冠状病毒试剂盒”等项目】新开源公告,公司已结合业内有关专家紧急立项利用Illumina高通量测序平台的“呼吸道冠状病毒试剂盒”及利用荧光定量PCR平台的新型冠状病毒核酸检测试剂盒项目,限于项目本身的研发周期,形成产品和获取相关批件的时间具有不确定性。同时,公司产品聚维酮碘(PVP-I)对于细菌、真菌、病毒、原虫等都有良好的杀灭作用。疫情爆发以来,公司收到了多家客户的应急订单,基本可以满足医药生产厂家的需求。

  • 【新开源:已立项“呼吸道冠状病毒试剂盒”等项目】新开源公告,公司已结合业内有关专家紧急立项利用Illumina高通量测序平台的“呼吸道冠状病毒试剂盒”及利用荧光定量PCR平台的新型冠状病毒核酸检测试剂盒项目,限于项目本身的研发周期,形成产品和获取相关批件的时间具有不确定性。同时,公司产品聚维酮碘(PVP-I)对于细菌、真菌、病毒、原虫等都有良好的杀灭作用。疫情爆发以来,公司收到了多家客户的应急订单,基本可以满足医药生产厂家的需求。

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐